

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on May 18, 2025

TotalSeq(TM)-C0088 anti-human CD279 (PD-1)

RRID:AB_2800862

Type: Antibody

Proper Citation

(BioLegend Cat# 329963, RRID:AB_2800862)

Antibody Information

URL: http://antibodyregistry.org/AB_2800862

Proper Citation: (BioLegend Cat# 329963, RRID:AB_2800862)

Target Antigen: CD279

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: PG

Antibody Name: TotalSeq(TM)-C0088 anti-human CD279 (PD-1)

Description: This monoclonal targets CD279

Target Organism: human

Clone ID: Clone EH12.2H7

Antibody ID: AB_2800862

Vendor: BioLegend

Catalog Number: 329963

Record Creation Time: 20231110T032755+0000

Record Last Update: 20240725T014117+0000

Ratings and Alerts

No rating or validation information has been found for TotalSeq(TM)-C0088 anti-human CD279 (PD-1).

No alerts have been found for TotalSeq(TM)-C0088 anti-human CD279 (PD-1).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Gupta T, et al. (2024) Tracking in situ checkpoint inhibitor-bound target T cells in patients with checkpoint-induced colitis. *Cancer cell*, 42(5), 797.

Reid KT, et al. (2024) Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses. *Cell reports*, 44(1), 115102.

Poch T, et al. (2024) Intergenic risk variant rs56258221 skews the fate of naive CD4+ T cells via miR4464-BACH2 interplay in primary sclerosing cholangitis. *Cell reports. Medicine*, 5(7), 101620.

Vyasamneni R, et al. (2023) A universal MHCII technology platform to characterize antigen-specific CD4+ T cells. *Cell reports methods*, 3(1), 100388.

Ivanova EN, et al. (2023) mRNA COVID-19 vaccine elicits potent adaptive immune response without the acute inflammation of SARS-CoV-2 infection. *iScience*, 26(12), 108572.

Mayer-Blackwell K, et al. (2023) mRNA vaccination boosts S-specific T cell memory and promotes expansion of CD45RA^{int} TEMRA-like CD8+ T cells in COVID-19 recovered individuals. *Cell reports. Medicine*, 4(8), 101149.

Sureshchandra S, et al. (2023) Multimodal profiling of term human decidua demonstrates immune adaptations with pregravid obesity. *Cell reports*, 42(7), 112769.

Kastenschmidt JM, et al. (2023) Influenza vaccine format mediates distinct cellular and antibody responses in human immune organoids. *Immunity*, 56(8), 1910.

Awad MM, et al. (2022) Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. *Cancer cell*, 40(9), 1010.

Collora JA, et al. (2022) Single-cell multiomics reveals persistence of HIV-1 in expanded cytotoxic T cell clones. *Immunity*, 55(6), 1013.

Welters C, et al. (2022) Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma. *Cancer immunology research*, 10(11), 1407.

Hanada KI, et al. (2022) A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers. *Cancer cell*, 40(5), 479.

Li SS, et al. (2022) HLA-B*46 associates with rapid HIV disease progression in Asian cohorts and prominent differences in NK cell phenotype. *Cell host & microbe*, 30(8), 1173.

Bachireddy P, et al. (2021) Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy. *Cell reports*, 37(6), 109992.

Shangguan S, et al. (2021) Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1. *eLife*, 10.